http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009209581-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35cfb213a727246cf215b38b860de65a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc1e74857262e51b02125ce47f6d705b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-00 |
| filingDate | 2006-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9eb04ae4fc78d7330861a642a327172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02d059c02f00b7be46ec04b995c5463e |
| publicationDate | 2009-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009209581-A1 |
| titleOfInvention | Nitroxides for use in treating or preventing immunological diseases |
| abstract | Pharmaceutical compositions are provided that are useful in treating immunological diseases. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of a gene related to an immunological disease. Methods are also provided for the use of the pharmaceutical compositions in the treatment or prevention of immunological disease. In a preferred embodiment, the nitroxide antioxidant is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl); the gene is one of glucocorticoid-induced leucine zipper, collagen type I alpha 1, and complement component 6; and the immunological disease is Graves' disease, Hashimoto's thyroiditis, autoimmune polyglandular syndrome, insulin-dependent diabetes mellitus, insulin-independent diabetes mellitus, immune-mediated infertility, autoimmune Addison's disease, pemphigus vulgaris, pemphigus foliaceus, dermatitis herpetiformus, vitiligo, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, pernicious anemia, myasthenia gravis, multiple sclerosis, Guillain-Barre syndrome, stiff-man syndrome, acute rheumatic fever, sympathetic ophthalmia, Goodpasture's syndrome, systemic lupus erythematosus, rheumatoid arthritis, systemic necrotizing vasculitis, Wegener's granulomatosis, antiphospholipid syndrome, Sjögren's syndrome, scleroderma, accelerated graft arteriosclerosis, graft-versus-host disease, Crohn's disease, or tuberculosis. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022378765-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018078539-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874654-B2 |
| priorityDate | 2005-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 312.